The Dana-Farber-led phase 1b/2 safety trial (n=36, randomized) published in Nature Cancer provides the first human validation of Ronald Evans' foundational work on vitamin D receptor (VDR) signaling in pancreatic fibroblasts. Unlike large observational cohorts linking serum 25(OH)D levels to outcomes, this RCT directly tested the FDA-approved analog paricalcitol alongside gemcitabine/nab-paclitaxel, demonstrating reduced fibroblast activation and a numerical progression-free survival edge at one year. The study was not powered for efficacy, yet patients with high tumoral VDR expression showed the longest overall survival, echoing Evans' 2014 Cell and 2016 PNAS preclinical data where VDR agonism reversed cancer-associated fibroblast activation in KPC mice without systemic hypercalcemia. Prior coverage overlooked the nuclear-receptor pharmacology context: roughly 13% of approved drugs target this superfamily, positioning paricalcitol as a rapid repurposing candidate rather than a novel entity. Conflicts of interest include Salk Institute equity ties and Dana-Farber industry collaborations; larger phase 3 trials with biomarker stratification are essential before claiming a treatment shift.